SCHEMBL2234794

SCHEMBL2234794

COC(=O)c1ncn(C)c1N

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.40
ALDH1A1 P00352 5/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 2/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.36
TSHR P16473 1/20 0.36
CFTR P13569 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1990691 0.81 ALDH1A1 (0.46) SMN1; SMN2CYP1A2ALDH1A1LMNAGAA
SCHEMBL13651660 0.79 NPSR1 (0.45) NPSR1TP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL71364 0.79 APOBEC3A (0.46) NPSR1ALDH1A1LMNAAPOBEC3AAPOBEC3G
SCHEMBL12255736 0.79 NPSR1 (0.45) NPSR1SMN1; SMN2ALDH1A1GAAAPOBEC3A
SCHEMBL5433650 0.79 LMNA (0.42) ALDH1A1LMNAGAAAPOBEC3AAPOBEC3G
SCHEMBL2112227 0.79 ALDH1A1 (0.59) TP53ALDH1A1LMNAAPOBEC3AAPOBEC3G
SCHEMBL13688644 0.79 ALDH1A1 (0.42) ALDH1A1LMNAAPOBEC3AAPOBEC3G
SCHEMBL31336867 0.78 KDM4E (0.44) NPSR1SMN1; SMN2ALDH1A1APOBEC3AAPOBEC3G
SCHEMBL19737998 0.78 NPSR1 (0.43) NPSR1SMN1; SMN2ALDH1A1APOBEC3AAPOBEC3G
SCHEMBL13651652 0.78 NPSR1 (0.43) NPSR1TP53SMN1; SMN2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759361-B2 2-phenoxy pyrimidinone analogues NEUROGEN CORPORATION (US) 2014-06-24 US disclosed
EP-2061794-B1 2-PHENOXY PYRIMIDINONE ANALOGUES NEUROGEN CORP (US) 2012-12-05 EP disclosed
US-20120208829-A1 2-PHENOXY PYRIMIDINONE ANALOGUES NEUROGEN CORPORATION (US) 2012-08-16 US disclosed
US-8003656-B2 2-phenoxy pyrimidinone analogues NEUROGEN CORPORATION (US) 2011-08-23 US disclosed
US-20090069347-A1 2-phenoxy pyrimidinone analogues NEUROGEN CORPORATION (US) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208829-A1 2-PHENOXY PYRIMIDINONE ANALOGUES GPR174, GPR17, PTGFR NPSR1 219/4885TP53 2897/4885SMN1; SMN2 1895/4885
US-20090069347-A1 2-phenoxy pyrimidinone analogues GPR174, GPR17, PTGFR NPSR1 219/4885TP53 2897/4885SMN1; SMN2 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.